

Record Revenues for FY25

- **Record revenues of A\$28.8m for the year ended 30 June 2025 and in line with guidance**
- **Six consecutive half-years of growth in the USA with H2FY25 US sales up 25% on pcp**
- **Q4FY25 sales of A\$8.4m the highest on record**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye** or the **Company**) is pleased to report a record sales result for FY25.

Group revenue for FY25 reached A\$28.8 million (US\$18.4 million), up 21% (in constant currency) from FY24.

Key drivers include:

- US sales of US\$14.2 million, up 25% with iTrack™ Advance delivering six consecutive half-years of revenue growth.
- H2FY25 sales A\$15.7 million (US\$10 million) up 46% on pcp (in constant currency) and in line with guidance
- Q4FY25 sales of A\$8.4 million (US\$5.4 million) were the highest on record

The record result underscores the continued adoption of iTrack™ Advance and growing global recognition of Nova Eye's technology.

Nova Eye expects revenue growth to continue in FY26.

Please refer to the Investor Presentation released today for additional details.

The Company expects to release its Quarterly Activities Report and Appendix 4C in the last week of July and its audited financial statements in late August 2025.

Investor Webinar - Managing Director Tom Spurling will discuss Nova Eye Medical's record sales results for the FY25 period.

- Date: Wednesday, 9 July 2025
- Time: 11.30am AEST
- Presenter: Tom Spurling, Nova Eye Medical Managing Director
- Registration Link: <https://us02web.zoom.us/webinar/register/>

Participants will have the opportunity to submit questions before the webinar by emailing mflynn@nova-eye.com or during the live Q&A session.

– ENDS –

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

For more information:

Company

Tom Spurling

Managing Director

+61 417 818 658

tspurling@nova-eye.com

Investors

Mark Flynn

Investor Relations

+61 416 068 733

mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:
www.nova-eye.com